Leerink: Trovagene Is A Pure Play That Should Outperform

In a report published Friday, Leerink analyst Dan Leonard initiated coverage of

with an Outperform rating and price target of $9. According to the Leerink report, "TROV is an early stage pure play in the cancer liquid biopsy market, a market with the potential in our view to be the largest in molecular diagnostics." The analyst believes that there could be large market opportunity for the company's products, while seeing TrovaGene as an early mover that has unique capabilities. While early studies have validated the test performance of the company's pipeline products, more data is expected going forward. For now, the early performance of these product, when compared to the company's plan, indicate clinical interest. The management team has already assembled to address the market opportunity.